Ligand Pharmaceuticals Incorporated (LGND) Earnings History
Profitable32 years of earnings data (1994–2025) · Positive TTM net income
Loading earnings history...
Ligand Pharmaceuticals Incorporated (LGND) Earnings Overview
As of June 22, 2026, Ligand Pharmaceuticals Incorporated (LGND) reported trailing twelve-month net income of $154M, reflecting +2886.4% year-over-year growth. The company earned $7.72 per diluted share over the past four quarters, with a net profit margin of 46.4%.
Looking at the long-term picture, LGND's historical earnings data spans multiple years. The company achieved its highest annual net income of $629M in fiscal 2019.
Ligand Pharmaceuticals Incorporated maintains industry-leading profitability with a gross margin of 97.5%, operating margin of 17.6%, and net margin of 46.4%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including PRGO (-$1.82B net income, -33.5% margin), INVA ($504M net income, 63.8% margin), OMAB ($5.34B net income, 33.5% margin), LGND has outperformed on profitability metrics. Compare LGND vs PRGO →
LGND Earnings vs Peers
Earnings metrics vs comparable public companies
LGND Historical Earnings Data (1994–2025)
32 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $124M | +3186.6% | $47M | $6.13 | 46.4% | 17.6% |
| 2024 | -$4M | -107.7% | -$23M | $-0.22 | -2.4% | -13.5% |
| 2023 | $52M | +256.3% | $12M | $2.94 | 39.7% | 9.1% |
| 2022 | -$33M | -158.4% | $3M | $-1.98 | -17.0% | 1.5% |
| 2021 | $57M | +2014.2% | $104M | $3.34 | 23.7% | 43.0% |
| 2020 | -$3M | -100.5% | $38M | $-0.18 | -1.8% | 22.9% |
| 2019 | $629M | +339.1% | $807M | $31.85 | 523.2% | 671.0% |
| 2018 | $143M | +1041.5% | $164M | $5.96 | 57.0% | 65.1% |
| 2017 | $13M | +867.5% | $68M | $0.53 | 8.9% | 48.2% |
| 2016 | -$2M | -100.6% | $44M | $-0.08 | -1.5% | 40.3% |
| 2015 | $257M | +2039.9% | $27M | $12.12 | 357.8% | 38.0% |
| 2014 | $12M | +5.3% | $20M | $0.56 | 18.6% | 30.4% |
| 2013 | $11M | +2267.2% | $15M | $0.55 | 23.3% | 30.5% |
| 2012 | $-527,000 | -105.2% | $574,000 | $-0.03 | -1.7% | 1.8% |
| 2011 | $10M | +181.3% | $-698,000 | $0.52 | 33.9% | -2.3% |
| 2010 | -$13M | -542.5% | -$29M | $-0.64 | -53.2% | -124.5% |
| 2009 | -$2M | +98.0% | -$10M | $-0.10 | -5.0% | -25.6% |
| 2008 | -$98M | -134.8% | -$97M | $-6.16 | -359.2% | -356.1% |
| 2007 | $282M | +987.4% | -$60M | $17.22 | 2184.6% | -466.7% |
| 2006 | -$32M | +12.8% | -$169M | $-2.36 | -22.5% | -119.7% |
| 2005 | -$36M | +19.4% | -$26M | $-2.95 | -20.6% | -15.0% |
| 2004 | -$45M | -20.5% | -$37M | $-3.68 | -27.6% | -22.9% |
| 2003 | -$37M | -14.9% | -$19M | $-3.18 | -26.5% | -13.6% |
| 2002 | -$33M | +24.2% | -$24M | $-2.83 | -33.7% | -25.0% |
| 2001 | -$43M | +40.6% | -$23M | $-4.34 | -56.3% | -30.3% |
| 2000 | -$72M | +3.1% | -$46M | $-7.80 | -150.4% | -95.4% |
| 1999 | -$75M | +36.6% | -$56M | $-9.51 | -182.6% | -137.7% |
| 1998 | -$118M | -17.7% | -$70M | $-17.51 | -666.1% | -393.2% |
| 1997 | -$100M | -168.6% | -$31M | $-18.15 | -193.8% | -59.6% |
| 1996 | -$37M | +41.9% | -$33M | $-7.78 | -101.4% | -89.4% |
| 1995 | -$64M | -136.9% | -$25M | $-17.19 | -262.0% | -101.6% |
| 1994 | -$27M | - | -$21M | $-9.42 | -203.8% | -157.1% |
Download Data
Export LGND earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
32+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
LGND — Frequently Asked Questions
Quick answers to the most common questions about buying LGND stock.
What is LGND earnings per share (EPS)?
LGND trailing twelve-month (TTM) diluted EPS is $7.72, reflecting +2886.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1994 to 2025 is available in the table on this page.
What is Ligand Pharmaceuticals Incorporated's net income?
Ligand Pharmaceuticals Incorporated (LGND) trailing twelve-month net income is $154M as of 2025. Earnings grew +2886.4% year-over-year.
Is LGND profitable?
Yes, LGND is profitable with a TTM net income of $154M and a net profit margin of +46.4%.
What is LGND's earnings growth rate?
LGND compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: -6.6%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1994 to 2025.
What are LGND's profit margins?
Ligand Pharmaceuticals Incorporated net profit margin is +46.4%, operating margin is +17.6%, and gross margin is +97.5%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +13.5%.
Is LGND growing earnings?
Yes, LGND earnings are accelerating — EPS growth of +2886.4% exceeds the 5-year CAGR of N/A. TTM net income reached $154M. Earnings momentum is strengthening.
What was LGND's best earnings year?
Ligand Pharmaceuticals Incorporated's highest annual net income on record is $629M, achieved in fiscal year 2019. Earnings history on this page spans 1994 to 2025 and includes all annual and quarterly figures.
What were LGND's earnings last quarter?
LGND's most recent reported quarter was Q1 2026. Net income was $-13M with diluted EPS of $-0.67. For a full breakdown of all quarters, see the quarterly earnings table on this page.